Skip to main content

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In What does "Remember Me" do?

Don't Know Your Password?
Help

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In

Don't Know Your Password?

Zacks

more

aTyr Pharma (LIFE)

(Delayed Data from NSDQ)

$NA USD

0 (0.00%)

Updated Dec 31, 1969 06:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.08%
2	Buy	17.91%
3	Hold	9.44%
4	Sell	5.10%
5	Strong Sell	2.55%
S&P	500	11.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Top 34% (84 out of 248)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

aTyr Pharma, Inc. [LIFE]

Reports for Purchase

Showing records 61 - 80 ( 174 total )

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 61

07/02/2021

Pages: 8

KOL Highlights Need in Sarcoidosis Ahead of ATYR1923''s Data in 3Q2021

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 62

06/30/2021

Pages: 7

The Final Setup; KOL Perspective Ahead of Critical Phase 1b/2a Sarcoidosis Data in 3Q21

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 63

05/14/2021

Pages: 7

1Q21 Results; Exciting Pipeline Developments While Waiting For Top-Line Data In Sarcoidosis in 3Q21

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 64

05/14/2021

Pages: 5

1Q21 Update - Sarcoidosis Data Expected in 3Q21, NRP Antibody IND in 4Q21

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 65

05/14/2021

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 66

04/12/2021

Pages: 6

AACR Highlights ATYR2810''s Mono and Combo Potential in TNBC and NSCLC

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 67

04/12/2021

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 68

04/09/2021

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 69

03/25/2021

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 70

03/24/2021

Pages: 7

2020 Results; Clinical Validation for ATYR1923 Continues Ahead of Sarcoidosis Data in 3Q21

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 71

03/24/2021

Pages: 6

4Q20 - Sarcoidosis Data in 3Q2021 Will Be a Major Value-inflection Point

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 72

03/16/2021

Pages: 7

COVID Patients'' Biomarker Data Validate ATYR1923''s MOA-Raising PT to $20

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 73

03/16/2021

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 74

03/15/2021

Pages: 5

ATYR1923 Delivers Key MoA''s Validation in the Clinic Ahead of Sarcoidosis Results in 3Q21

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 75

03/11/2021

Industry Report

Pages: 3

Our Covered Companies Will Present at AACR

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 76

01/29/2021

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 77

01/28/2021

Pages: 6

New Data Highlight Why NRP2 Is a Cancer Target Not to Be Ignored

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 78

01/20/2021

Pages: 6

ATYR1923 Positioned Well for 2021 and Beyond; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 79

01/19/2021

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 80

01/15/2021

Pages: 5

Another Milestone Reached in Steps to Get 1923 Approved in Japan for ILDs

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party